Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence
Статины в профилактике и лечении сердечной недостаточности: обзор доказательств
2019-07-27
SCID: 54.1/xd6qq4te
Discuss with AI
cardiovascular deathheart failureheart failure hospitalizationmyocardial infarctionstatins
Figures from the paper
Abstract (AI)
PURPOSE OF REVIEW: We summarize the best evidence for statins in the prevention and treatment of heart failure. RECENT FINDINGS: In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease (but without heart failure), statins reduce the risk of incident heart failure-mainly by preventing myocardial infarction although an additional benefit from reducing myocardial ischemia cannot be excluded. However, in patients with established heart failure, statins do not reduce the risk of cardiovascular death, which is mainly caused by pump failure and ventricular arrhythmias. Retrospective analyses, however, suggest that statins may reduce the rate of heart failure hospitalization and atherosclerotic events (which are proportionately much less common in these patients than heart failure hospitalization or death). Statin therapy should probably be continued in patients with coronary artery disease developing heart failure, although the weak evidence and small benefit may not justify the use of this treatment in very elderly patients with a short life expectancy and in which polypharmacy is a problem.
Key Findings
1
Among patients with established heart failure, statins do not reduce cardiovascular mortality, which is primarily driven by pump failure and ventricular arrhythmias.
2
An additional reduction in heart failure risk through decreased myocardial ischemia cannot be excluded, although the abstract does not establish this mechanism.
3
In patients with cardiovascular risk factors or established atherosclerotic cardiovascular disease without heart failure, statins reduce incident heart failure risk, mainly by preventing myocardial infarction.
4
Retrospective analyses suggest statins may reduce heart failure hospitalizations and atherosclerotic events, although these events are less frequent than heart failure hospitalization or death.
5
Statins should probably be continued when coronary artery disease progresses to heart failure, but limited benefit may not justify treatment in very elderly patients with short life expectancy and problematic polypharmacy.
Research Object
statin therapy in patients with cardiovascular risk factors, atherosclerotic cardiovascular disease, or established heart failure
Research Subject
the effects of statins on incident heart failure, heart-failure hospitalization, cardiovascular mortality, and atherosclerotic events
Publication Details
Publication Date
2019-07-27
Journal
Publisher
ISSN
Cited by
95
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest